Download PDF
Transfusionsmedizin 2015; 5(1): 13-19
DOI: 10.1055/s-0034-1396189
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Rationale Indikationsstellung zur Thrombozytenkonzentrat-Transfusion

Blutungsrisiken beachtenRational Indication of Platelet TransfusionTake Care of Bleeding Risks
H. Wandt
1   Medizinische Klinik 5, Hämatologie und Onkologie, Paracelsus Medizinische Privatuniversität Nürnberg
,
K. Schäfer-Eckart
1   Medizinische Klinik 5, Hämatologie und Onkologie, Paracelsus Medizinische Privatuniversität Nürnberg
,
A. Greinacher
2   Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald
› Author Affiliations
Further Information

Publication History

Publication Date:
11 February 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Bisher wird routinemäßig bei akuter hypoproliferativer Thrombozytopenie eine prophylaktische Thrombozytentransfusion empfohlen. Bei chronischer Thrombozytopenie wurde schon länger ein restriktiveres Vorgehen im Sinne einer vorwiegend therapeutischen Transfusionsstrategie vorgeschlagen. In Deutschland werden aktuell jährlich eine halbe Million Thrombozytentransfusionen verabreicht mit weiter steigender Tendenz. Die weitaus meisten Thrombozytentransfusionen werden bei hämatologischen und onkologischen Patienten verbraucht. Untersuchungen besagen, dass die Hämotherapie-Leitlinien nicht überall und nicht konsequent eingehalten werden. Neue Studien weisen auf die Möglichkeit einer therapeutischen Transfusionsstrategie für klinisch stabile Patienten hin, die ein niedriges Blutungsrisiko haben wie z. B. nach autologer hämatopoetischer Blutstammzelltransplantation. Patienten mit hohem Blutungsrisiko wie z. B. bei akuter Leukämie sollen unverändert außerhalb von Studien prophylaktisch transfundiert werden. Dabei hat sich die Transfusion ab einem Thrombozytengrenzwert von 10 000/µL ohne Einschränkung als sicher erwiesen, solange keine Blutungszeichen vorliegen. Insgesamt ließe sich durch eine rationale Indikationsstellung der Verbrauch an Thrombozytenkonzentraten deutlich senken. Der morgendlich gemessene Thrombozytenwert allein lässt bei thrombozytopenischen Patienten das Risiko für klinisch relevante Blutungen nicht vorhersagen. Das Risiko wird wesentlich durch die klinischen Faktoren des Patienten bestimmt. Um schwerwiegende Blutungen zu vermeiden, ist es wichtig, auf erste Zeichen von Blutungen zu achten und nicht allein auf den morgendlichen Thrombozytenwert. Eine entsprechende Schulung der Patienten und des medizinischen Personals ist dafür erforderlich.

Abstract

To date, routine prophylactic platelet transfusion is recommended in acute hypoproliferative thrombocytopenia. In chronic thrombocytopenia a more restrictive strategy has been proposed since many years that leads mainly to a therapeutic transfusion strategy. In Germany, to date, half a million of platelet transfusions per year have been performed. By far, most platelet transfusions are used in haematology and oncology patients. Studies have shown that hematotherapy guidelines are not followed strictly enough in many hospitals. According to recent trials clinically stable patients who are at low risk for bleeding – e.g. patients who have undergone autologous hematopoietic stem cell transplantation – can be treated by a therapeutic transfusion strategy. Patients with a high bleeding risk as e.g. with acute leukaemia should still receive a prophylactic transfusion. In patients without bleeding signs a transfusion trigger of 10 000/µL without any modification has been proven to be safe. In conclusion, the number of platelet transfusions could be lowered significantly if a rational strategy of transfusion would be followed. The risk of clinically relevant bleeding in thrombocytopenic patients can not be predicted exclusively by the morning platelet count. This risk is mainly due to clinical factors of the patient. Taking care of first signs of hemorrhage is important to avoid severe bleeding and not only the morning platelet count. Appropriate training of patients and medical staff is required.

Schlüsselwörter

Thrombozytentransfusion - Thrombozytopenie - Blutungsrisiko - prophylaktische und therapeutische Thrombozytentransfusion - Bedarf nach Thrombozytentransfusion

Key words

platelet transfusion - thrombocytopenia - bleeding risk - prophylactic and therapeutic platelet transfusion - demand of platelet transfusion
 

  • Literatur

  • 1 Wandt H, Schäfer-Eckart K, Grinacher A. Platelet transfusion in hematology, oncology and surgery. Dtsch Arztebl Int 2014; 111: 809-815
    PubMedGoogle Scholar
  • 2 Estcourt LJ. Why has demand for platelet component increased? A review. Transfus Med 2014; 24: 260-268
    CrossrefPubMedGoogle Scholar
  • 3 Bundesärztekammer. Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten – Herausgegeben von der Bundesärztekammer auf Empfehlung ihres Wissenschaftlichen Beirats. 4.. Aufl. Köln: Deutscher Ärzte-Verlag; 2009
    Google Scholar
  • 4 Blumberg N, Heal JM, Phillips GL et al. Platelets – to transfuse or not to transfuse. Lancet 2012; 380: 1287-1289
    CrossrefPubMedGoogle Scholar
  • 5 Refaai MA, Phipps RP, Spinelli SL et al. Platelet transfusions: impact on hemostasis, thrombosis, inflammation and clinical outcomes. Thromb Res 2011; 127: 287-291
    CrossrefPubMedGoogle Scholar
  • 6 Gaydos LA, Freirecht EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962; 266: 905-909
    CrossrefPubMedGoogle Scholar
  • 7 Gmür J, Burger J, Schanz U et al. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 1991; 338: 1223-1226
    CrossrefPubMedGoogle Scholar
  • 8 Rebulla P, Finanzzi G, Marangoni F et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dellʼAdulto. N Engl J Med 1997; 337: 1870-1875
    CrossrefPubMedGoogle Scholar
  • 9 Wandt H, Frank M, Ehninger G et al. Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998; 91: 3601-3606
    PubMedGoogle Scholar
  • 10 Heckman KD, Weiner GJ, Davis CS et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/µL versus 20,000/µL. J Clin Oncol 1997; 15: 1143-1149
    PubMedGoogle Scholar
  • 11 Schiffer CA, Anderson KC, Bennet CL et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1519-1538
    CrossrefPubMedGoogle Scholar
  • 12 British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haemat 2003; 122: 10-23
    CrossrefPubMedGoogle Scholar
  • 13 Estcourt L, Stanworth S, Doree C et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev 2012; (5) CD004269
    PubMedGoogle Scholar
  • 14 Estcourt LJ, Heddle N, Kaufman R et al. The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion 2013; 53: 1531-1543
    CrossrefPubMedGoogle Scholar
  • 15 Webert KE, Arnold DM, Lui Y et al. A new tool to assess bleeding severity in patients with chemotherapy-induced thrombocytopenia. Transfusion 2012; 52: 2466-2474
    CrossrefPubMedGoogle Scholar
  • 16 Friedmann AM, Sengul H, Lehmann H et al. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev 2002; 16: 34-45
    CrossrefPubMedGoogle Scholar
  • 17 Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev 2004; 18: 153-167
    CrossrefPubMedGoogle Scholar
  • 18 Schiffer CA. Prophylactic platelet transfusion is frequently not necessary. Nat Rev Clin Oncol 2013; 10: 431-432
    CrossrefPubMedGoogle Scholar
  • 19 Webbert KE, Cook RJ, Sigouin CS et al. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica 2006; 91: 1530-1537
    PubMedGoogle Scholar
  • 20 Sagemeister M, Oec L, Gmür J. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood 1999; 93: 3124-3126
    PubMedGoogle Scholar
  • 21 Wandt H, Schaefer-Eckart K, Wendelin K et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomized study. Lancet 2012; 380: 1309-1316
    CrossrefPubMedGoogle Scholar
  • 22 Stanworth SJ, Estcourt LJ, Powter G et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med 2013; 368: 1771-1780
    CrossrefPubMedGoogle Scholar
  • 23 Wandt H, Schaefer-Eckart K, Frank M et al. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37: 387-392
    CrossrefPubMedGoogle Scholar
  • 24 Goerge T, Ho-Tin-Noe B, Carbo C et al. Inflammation induces hemorrhage in thrombocytopenia. Blood 2008; 111: 4958-4964
    CrossrefPubMedGoogle Scholar
  • 25 Morowski M, Vögtle T, Kraft P et al. Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice. Blood 2013; 121: 4938-4947
    CrossrefPubMedGoogle Scholar
  • 26 Ho-Tin-Noe B, Demers M, Wagner DD. How platelets safeguard vascular integrity. J Thromb Haemost 2011; 9 (Suppl. 01) S56-S65
    CrossrefPubMedGoogle Scholar
  • 27 Ho-Tin-Noe B, Carbo C, Demers M et al. Innate immune cells induce hemorrhage in tumors during thrombocytopenia. Am J Pathol 2009; 175: 1699-1708
    CrossrefPubMedGoogle Scholar
  • 28 Slichter SJ, Harker LA. Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol 1978; 7: 523-539
    PubMedGoogle Scholar
  • 29 Greinacher A, Kiefel V, Klüter H et al. Empfehlung zur Thrombozytentransfusion der Thrombozyten-Arbeitsgruppe der DGTI, GTH und DGHO. Transfus Med Hemother 2006; 33: 528-543
    CrossrefPubMedGoogle Scholar
  • 30 Neunert C, Lim W, Crowther M et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190-4207
    CrossrefPubMedGoogle Scholar
  • 31 Slichter SJ, Kaufman RM, Assmann SF et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362: 600-613
    CrossrefPubMedGoogle Scholar
  • 32 Kaufman RM, Djulbegovic B, Gernsheimer T et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2014; DOI: 10.7326/M14-1589.
    PubMedGoogle Scholar
  • 33 Stanworth SJ, Estcourt LJ, Llewelyn CA et al. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. Transfusion 2014; 54: 2385-2393
    CrossrefPubMedGoogle Scholar
  • 34 Wardrop D, Estcourt LJ, Brunskill SJ et al. Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. Cochrane Database Syst Rev 2013; (7) CD009733
    PubMedGoogle Scholar
  • 35 Schiffer CA. They took a mulligan and mostly got it right… the issue of prophylactic platelet transfusion for patients receiving autologous stem cell transplantation. Transfusion 2014; 54: 2372-2374
    CrossrefPubMedGoogle Scholar
  • 36 Schaefer-Eckart K, Wendelin K, Pilz B et al. Consolidation therapy is associated with significantly lower bleeding risk compared to induction therapy in patients with acute myeloid leukemia. Blood 2014; 124: 3686
    PubMedGoogle Scholar
  • 37 Campbell HE, Estcourt JS, Stokes EA et al. Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion 2014; 54: 2394-2403
    CrossrefPubMedGoogle Scholar
  • 38 Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214
    CrossrefPubMedGoogle Scholar